WO2013177098A1 - Procédé de traitement d'états neurologiques - Google Patents
Procédé de traitement d'états neurologiques Download PDFInfo
- Publication number
- WO2013177098A1 WO2013177098A1 PCT/US2013/041925 US2013041925W WO2013177098A1 WO 2013177098 A1 WO2013177098 A1 WO 2013177098A1 US 2013041925 W US2013041925 W US 2013041925W WO 2013177098 A1 WO2013177098 A1 WO 2013177098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- csf
- antigen
- antibody
- treatment
- stage
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 29
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 63
- 239000000427 antigen Substances 0.000 claims abstract description 38
- 102000036639 antigens Human genes 0.000 claims abstract description 33
- 108091007433 antigens Proteins 0.000 claims abstract description 33
- 230000002964 excitative effect Effects 0.000 claims abstract description 12
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 12
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 claims description 14
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Chemical compound OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 claims description 14
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 8
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 claims description 7
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 claims description 7
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 claims description 7
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 claims description 7
- 229940009098 aspartate Drugs 0.000 claims description 7
- 229930195712 glutamate Natural products 0.000 claims description 7
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- VZFRNCSOCOPNDB-AOKDLOFSSA-N domoic acid Chemical compound OC(=O)[C@H](C)\C=C\C=C(\C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VZFRNCSOCOPNDB-AOKDLOFSSA-N 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000008685 targeting Effects 0.000 abstract description 6
- 238000000502 dialysis Methods 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 8
- 208000030886 Traumatic Brain injury Diseases 0.000 description 7
- 230000009529 traumatic brain injury Effects 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 208000017004 dementia pugilistica Diseases 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003090 exacerbative effect Effects 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011973 continuous veno-venous hemofiltration Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- Excitatory neurotransmitters are implicated as causing or exacerbating multiple neurologic conditions. This application utilizes a novel methodology for reducing the symptomatology and pathology of those neurologic morbidities which are exacerbated by excitatory neurotransmitters. Those neurologic dysfunctions include:
- TBI Traumatic brain injury
- ALS Amyotrophic lateral sclerosis
- a seizure is an abnormal irregular cortical discharge. Approximately 2% of all adults have a seizure at some time during their lifetime. Two thirds of these patients go on to have further seizures. About 40 million people are affected worldwide by seizure disorders. Epilepsy can arise from a variety of underlying conditions and pathophysiologic mechanisms.
- TBI traumatic brain injury
- CTE Chronic Traumatic Encephalopathy
- Cerebral vascular accident (CVA/strokes) is the fourth leading cause of death in United States. About 750,000 new strokes occur every year in United States and 150,000 people die from stroke each year. The incidence of CVA increases with age, two thirds of old strokes occur in patients over 65 years of age. The incidence of stroke is higher in men than women. The care of patients who suffer morbidity from a cerebrovascular accident is a major cause underlying the rapid increase in healthcare funding in the United States. The release of excitatory
- neurotransmitters during a cerebrovascular accident is implicated as a main etiology underlying an increase in morbidity and mortality from a CVA.
- the present invention relates to a method of extracorporeally treating animal or human cerebrospinal fluid (CSF) for the extracorporeal removal of excitatory neurotransmitters (EN).
- CSF cerebrospinal fluid
- EN excitatory neurotransmitters
- the invention pertains to a method for the extracorporeal treatment of CSF in two stages characterized by passing the CSF through a first stage; applying a treatment to at least one antigen in the CSF to create a antibody-antigen moiety during passage thereof through said first stage; passing the treated CSF through a second stage; and removing the treatment
- the method is further characterized by targeting an a excitatory neurotransmitter antigen (EN ) in the CSF , with an antibody to allow and facilitate removal thereof in the second stage.
- EN excitatory neurotransmitter antigen
- the targeted excitatory neurotransmitter (EN) antigens would include one, or a combination of : glutamate, aspartate, quinolinic acid, homocysteic acid, N-acetylaspartylglutamate (NAAG), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), N-methyl-D-aspartate (NMD A), Quisqualate , Kainate, Ibotenate and Domoate
- the method is characterized by directing a first antibody against the targeted EN antigen in the first stage; and directing a second antibody conjugated with albumin and /or a protein against the targeted antigen thereby forming an albumin-antibody-EN antigen compound in the second stage; and removing at least a portion of the albumin-antibody-EN antigen compound from the CSF.
- the method is further characterized by removing CSF from a person to produce the extracorporeal bodily fluid; and returning the CSF to the patient after substantially removing the treatment in the second stage.
- the method is characterized by testing the CSF to determine the efficacy of treatment before returning the CSF to the person.
- the CSF is removed utilizing a standard lumbar puncture.
- the CSF is treated with antibodies against the excitatory neurotransmitter (EN) antigen.
- EN excitatory neurotransmitter
- Figure 1 is a partial cross sectional view of a cylinder and tubing used to deliver a treatment to a bodily fluid.
- Figure 2 is a partial cross sectional view showing additional detail of the cylinder and tubing of Figure 1.
- the method of the present invention comprises treating a patient's CSF extracorporeally with a designer antibody containing an albumin moiety which will allow for the efficacious dialysis of the resultant albumin-antibody-EN antigen compound (the targeted EN antigen being respectively, one or a combination of : glutamate, aspartate, quinolinic acid, homocysteic acid, N-acetylaspartylglutamate (NAAG), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), N-methyl-D-aspartate (NMD A), Quisqualate , Kainate, Ibotenate and Domoate ), utilizing standard dialysis methodologies.
- the targeted EN antigen being respectively, one or a combination of : glutamate, aspartate, quinolinic acid, homocysteic acid, N-acetylaspartylglutamate (NAAG), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionat
- the albumin-antibody will be directed towards the removal of the targeted EN antigen(s), (glutamate, aspartate, quinolinic acid, homocysteic acid, N-acetylaspartylglutamate (NAAG), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), N-methyl-D-aspartate (NMD A), Quisqualate, Kainate, Ibotenate and Domoate).
- EN antigen(s) Glutamate, aspartate, quinolinic acid, homocysteic acid, N-acetylaspartylglutamate (NAAG), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), N-methyl-D-aspartate (NMD A), Quisqualate, Kainate, Ibotenate and Domoate.
- EN antigen(s) glutamino-3-hydroxy-5-methylisoxazole-4-propionate
- NMD A N
- the article includes two-stages.
- the first stage includes a treatment chamber which utilizes an antibody with an attached albumin moiety, which is added to the CSF.
- a second stage receives the treated CSF and includes a unit for removing the treatment.
- the method includes providing a dialysis machine with a first stage and a second stage, and sequentially passing the extracorporeal bodily fluid through the first and second stages.
- the CSF is removed from the patient utilizing standard lumbar puncture procedure.
- the first stage applies a treatment utilizing an antibody which was has attached to it an albumin moiety (or alternatively, a moiety which allows for the efficacious dialysis of the antibody-EN antigen), for the treatment of the CSF.
- the second stage substantially removes the treatment.
- the purified CSF (CSF with removed targeted EN : glutamate, aspartate, quinolinic acid, homocysteic acid, N-acetylaspartylglutamate (NAAG), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), N-methyl-D-aspartate (NMD A), Quisqualate , Kainate, Ibotenate and Domoate)- is then returned to the patient.
- the device of the intervention includes a first stage and a second stage.
- the first stage applies a treatment of an antibody with an attached albumin moiety targeting the EN antigen(s) specifically exacerbating the pathologic condition.
- the second stage includes substantial removal of the treatment from the extracorporeal CSF bodily fluid.
- the first stage can include an exterior wall to define a treatment chamber 5.
- the treatment conveniently can be applied in the treatment chamber 5. Residence times of the CSF can be altered by changing the dimensions of the treatment chamber, or by using a dialysis vacuum pump.
- CSF fluid enters the inlet 3, passes through the treatment chamber 5, and exits the outlet 4.
- the treatment of an antibody with an attached albumin moiety targeting the EN antigens can be applied from a delivery tube 6 located within the treatment chamber 5.
- An inferior wall 9 defines the delivery tube 6.
- the delivery tube 6 can include at least one lead 7, 8.
- the lead 7, 8 can deliver the treatment to the treatment chamber 5.
- the delivery tubes 6 will have a high contact surface area with the CSF.
- the delivery tube 6 comprises a helical coil.
- the delivery tube 6 when the treatment includes the administration of a designer antibody, can be hollow and the interior wall 9 can define a plurality of holes 21.
- the designer antibodies can be pumped through the delivery tube 6 in order to effect a desired concentration of designer antibodies in the CSF.
- the designer antibodies can perfuse through the holes 21.
- the delivery tube 6 can include any suitable material including, for example, metal, plastic, ceramic or combinations thereof.
- the delivery tube 6 can also be rigid or flexible.
- the delivery tube 6 is a metal tube perforated with a plurality of holes.
- the delivery tube 6 can be plastic.
- the antibody with attached albumin moiety, targeting the EN antigen(s) can be delivered in a concurrent or counter-current mode with reference to the CSF.
- the CSF enters the treatment chamber 5 at the inlet 3.
- the designer antibody can enter through a first lead 8 near the outlet 4 of the treatment chamber 5.
- CSF then passes to the outlet 4 and the designer antibodies pass to the second lead 7 near the inlet 3.
- the removal module of the second stage substantially removes the designer antibodies-antigen molecular compound from the CSF.
- the second stage can include a filter, such as a dialysis machine, which is known to one skilled in the art.
- the second stage can include a molecular filter.
- MARS molecular adsorbents recirculating system
- MARS technology can be used to remove small to average sized molecules from the CSF. Artificial liver filtration presently uses this technique.
- the method can include a plurality of steps for removing the targeted EN antigens
- a first step can include directing a first antibody against the targeted antigen.
- a second step can include a second antibody.
- the second antibody can be conjugated with albumen, or alternatively a moiety which allows for efficacious dialysis.
- the second antibody or antibody-albumen complex combines with the first antibody forming an antibody-antibody-moiety complex.
- a third step is then utilized to remove the complex from the CSF. This removal is enabled by utilizing dialysis and/or MARS.
- the purified CSF can then be returned to the patient.
- a portion of the purified CSF can be tested to ensure a sufficient portion of the targeted EN antigen(s), (glutamate, aspartate, quinolinic acid, homocysteic acid,
- N-acetylaspartylglutamate NAAG
- alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate AMPA
- N-methyl-D-aspartate N-methyl-D-aspartate
- quisqualate quisqualate, kainate, ibotenate and domoate
- the second stage to remove the antibody-moiety-targeted EN antigen complex by various techniques including, for example, filtering based on molecular size, protein binding, solubility, chemical reactivity, and combinations thereof.
- a filter can include a molecular sieve, such as zeolite, or porous membranes that capture complexes comprising molecules above a certain size.
- Membranes can comprise polyacrylonitrile, polysulfone, polyamides, cellulose, cellulose acetate, polyacrylates, polymethylmethacrylates, and combinations thereof.
- Increasing the flow rate or diasylate flow rate can increase the rate of removal of the antibody with attached albumin moiety targeting the EN antigen(s): glutamate, aspartate, quinolinic acid, homocysteic acid, N-acetylaspartylglutamate (NAAG), alpha-amino- 3-hydroxy-5-methylisoxazole-4-propionate (AMPA), N-methyl-D-aspartate (NMDA), quisqualate, kainate, ibotenate and domoate.
- EN antigen(s) glutamate, aspartate, quinolinic acid, homocysteic acid, N-acetylaspartylglutamate (NAAG), alpha-amino- 3-hydroxy-5-methylisoxazole-4-propionate (AMPA), N-methyl-D-aspartate (NMDA), quisqualate, kainate, ibotenate and domoate.
- CR RT continuous renal replacement therapy
- Categories of CRRT include continuous arteriovenous hemofiltration, continuous venovenous hemofiltration, continuous arteriovenous hemodiafiltration, slow continuous filtration, continuous arteriovenous high-flux hemodialysis, and continuous venovenous high flux hemodialysis.
- the sieving coefficient (SC) is the ratio of the molecular concentration in the filtrate to the incoming CSF. A SC close to zero implies that the moiety-antibody-targeted antigen complex will not pass through the filter. A filtration rate of 50 mL per minute is generally satisfactory.
- Other methods of increasing the removability of the moiety- antibody- targeted antigen include the use of temporary acidification of the CSF utilizing organic acids to compete with protein binding sites.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- External Artificial Organs (AREA)
Abstract
La présente invention concerne un procédé de traitement extracorporel du liquide céphalorachidien (LCR) d'un animal ou d'un être humain en vue de l'élimination extracorporelle de neurotransmetteurs excitatoires (EN). En particulier, l'invention concerne un procédé de traitement extracorporel du LCR en deux étages, caractérisé par le passage du LCR à travers un premier étage ; l'administration d'un traitement dirigé contre au moins un antigène dans le LCR pour générer un fragment anticorps-antigène lors de son passage à travers ledit premier étage ; le passage du LCR traité à travers un deuxième étage ; et l'élimination du traitement (fragment anticorps-antigène) du LCR lors du passage à travers ledit deuxième étage. Le procédé est en outre caractérisé par le ciblage d'un antigène de neurotransmetteur excitatoire (EN) dans le LCR, au moyen d'un anticorps pour permettre et faciliter son élimination dans le deuxième étage.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650843P | 2012-05-23 | 2012-05-23 | |
| US61/650,843 | 2012-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2013177098A1 true WO2013177098A1 (fr) | 2013-11-28 |
Family
ID=49624274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2013/041925 WO2013177098A1 (fr) | 2012-05-23 | 2013-05-21 | Procédé de traitement d'états neurologiques |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2013177098A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024072910A1 (fr) * | 2022-09-27 | 2024-04-04 | Marv Enterprises, LLC | Compositon pour diminuer de manière aiguë les effets physiopathologiques d'une commotion et procédé d'administration associé |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003815A1 (fr) * | 1993-07-30 | 1995-02-09 | Georgetown University | Anticorps specifiques de l'acide quinolinique |
| US20080195024A1 (en) * | 2005-07-20 | 2008-08-14 | Schmid-Schonbein Geert W | Treating Disorders Associated with Inflammation |
| US20100030196A1 (en) * | 2008-07-29 | 2010-02-04 | Medtronic, Inc. | Apheresis of a target molecule from cerebrospinal fluid |
| US20110295175A1 (en) * | 2010-03-16 | 2011-12-01 | Marv Enterprises Llc | Sequential Extracoporeal Treatment of Bodily Fluids |
-
2013
- 2013-05-21 WO PCT/US2013/041925 patent/WO2013177098A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003815A1 (fr) * | 1993-07-30 | 1995-02-09 | Georgetown University | Anticorps specifiques de l'acide quinolinique |
| US20080195024A1 (en) * | 2005-07-20 | 2008-08-14 | Schmid-Schonbein Geert W | Treating Disorders Associated with Inflammation |
| US20100030196A1 (en) * | 2008-07-29 | 2010-02-04 | Medtronic, Inc. | Apheresis of a target molecule from cerebrospinal fluid |
| US20110295175A1 (en) * | 2010-03-16 | 2011-12-01 | Marv Enterprises Llc | Sequential Extracoporeal Treatment of Bodily Fluids |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024072910A1 (fr) * | 2022-09-27 | 2024-04-04 | Marv Enterprises, LLC | Compositon pour diminuer de manière aiguë les effets physiopathologiques d'une commotion et procédé d'administration associé |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8834400B2 (en) | Artificial kidney | |
| US20110295175A1 (en) | Sequential Extracoporeal Treatment of Bodily Fluids | |
| US20180169319A1 (en) | Treatment of cancer by manipulating the immune system | |
| US20140251917A1 (en) | Method for the treatment of multiple sclerosis | |
| US20210283323A1 (en) | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome | |
| EP2934619B1 (fr) | Dispositif d'élimination des toxines liées aux protéines dans le plasma sanguin | |
| US9216386B2 (en) | Sequential extracorporeal treatment of bodily fluids | |
| CN112672756A (zh) | 低容量血浆置换用于治疗早期和中期的阿尔茨海默病的用途 | |
| US20140193514A1 (en) | Method for the Treatment of Cancer | |
| US20140037656A1 (en) | Treatment for Tauopathies | |
| DE19854338A1 (de) | Verfahren und Einrichtung zur Nierenersatztherapie | |
| WO2013177098A1 (fr) | Procédé de traitement d'états neurologiques | |
| WO2009103553A2 (fr) | Dialyse de bioéquivalence | |
| WO2013177104A2 (fr) | Traitement de tauopathies | |
| WO2015171270A1 (fr) | Procédé de traitement de neurofibromatose | |
| DE102004037475A1 (de) | Filtersystem zur membrangetrennten, adsorptiven Behandlung partikelhaltiger Flüssigkeiten | |
| US20180036349A1 (en) | Treatment for Chronic Pain | |
| US20150079098A1 (en) | Method of treating cancer | |
| US20170065717A1 (en) | Method for treating muscular dystrophy | |
| US20190125956A1 (en) | Treatment for Athersclerosis | |
| US20150071935A1 (en) | Treatment for the rapid amelioration of clinical depression | |
| JP6501425B2 (ja) | Ａβ除去システム | |
| US20170049950A1 (en) | Method for slowing the aging process | |
| WO2013142449A2 (fr) | Traitement de syndromes de douleur chronique | |
| DE202019105720U1 (de) | Membran und Vorrichtung zur Behandlung des Restless-Legs-Syndroms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13793320 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13793320 Country of ref document: EP Kind code of ref document: A1 |